Frankreich

DGAP-News: Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy

Abivax, Medical specialties, Hepatocellular carcinoma, Cancer, Clinical medicine, Medicine, Autoimmune diseases, Transgene SA, COVID-19 drug repurposing research
Vendredi, mars 5, 2021 - 8:01pm

The study has a robust randomized, double-blind and placebo-controlled design to test whether ABX464 could prevent the development of severe Covid-19 disease in the participants.

Key Points: 
  • The study has a robust randomized, double-blind and placebo-controlled design to test whether ABX464 could prevent the development of severe Covid-19 disease in the participants.
  • The DSMB recommendation is based on a planned, interim analysis evaluating data of 305 high-risk Covid-19 patients who completed the study period.
  • Abivax, a clinical stage biotechnology company, is modulating the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer.
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

2CRSi SA: Information following the initiation of the receivership procedure of Blade SAS. Revised revenue target for 2020/21: €162-175 million.

Computing, Computer engineering, Server hardware, Electronic engineering, Cloud infrastructure, Blade server, Cloud computing, Graphics processing unit
Mercredi, mars 3, 2021 - 8:02pm

The company Blade SAS, the specialist of cloud PC for video game players, was placed in receivership proceedings by the Paris Commercial Court yesterday.

Key Points: 
  • The company Blade SAS, the specialist of cloud PC for video game players, was placed in receivership proceedings by the Paris Commercial Court yesterday.
  • In all contracts between the two companies, the servers provided remain the property of 2CRSi [1] until all lease payments or instalments are paid by Blade.
  • These servers that 2CRSi could take over are high-end graphics card (GPU) based compute servers and storage servers.
  • The financial debt corresponding to the financing of the contracts with Blade SAS amounts to 3.7 million as of today.

DGAP-News: Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal 'Gastroenterology'

Medical specialties, Clinical medicine, Immunology, Autoimmune diseases, Abdominal pain, Monoclonal antibodies, Colitis, Abivax, Ulcerative colitis, Crohn's disease, Vedolizumab, Infliximab
Mercredi, mars 3, 2021 - 6:02pm

The peer-reviewed article scientifically confirms the quality and robustness of the data generated in Abivax's randomized placebo-controlled, double-blind clinical study that consisted of an eight-week induction phase followed by an open-label long-term extension phase .

Key Points: 
  • The peer-reviewed article scientifically confirms the quality and robustness of the data generated in Abivax's randomized placebo-controlled, double-blind clinical study that consisted of an eight-week induction phase followed by an open-label long-term extension phase .
  • Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: "We are proud that "Gastroenterology" accepted the exciting results of our induction and long-term phase 2a maintenance study in moderate-to-severe ulcerative colitis patients with ABX464.
  • Therefore, we are preparing to move our lead molecule into a phase 3 clinical program in ulcerative colitis and to initiate a phase 2b/3 clinical trial in Crohn's disease.
  • ABX464 is currently being evaluated in a phase 2b UC clinical trial, a phase 2b/3 Covid-19 clinical trial and a phase 2a rheumatoid arthritis clinical trial.